Abstract:In the world plagued by the emergence of new diseases, it is essential that we accelerate the drug design process to develop new therapeutics against them. In recent years, deep learning-based methods have shown some success in ligand-based drug design. Yet, these methods face the problem of data scarcity while designing drugs against a novel target. In this work, the potential of deep learning and molecular modeling approaches was leveraged to develop a drug design pipeline, which can be useful for cases where there is limited or no availability of target-specific ligand datasets. Inhibitors of the homologues of the target protein were screened at the active site of the target protein to create an initial target-specific dataset. Transfer learning was used to learn the features of the target-specific dataset. A deep predictive model was utilized to predict the docking scores of newly designed molecules. Both these models were combined using reinforcement learning to design new chemical entities with an optimized docking score. The pipeline was validated by designing inhibitors against the human JAK2 protein, where none of the existing JAK2 inhibitors were used for training. The ability of the method to reproduce existing molecules from the validation dataset and design molecules with better binding energy demonstrates the potential of the proposed approach.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c01060?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c01060</a>.Supporting Information 1: details of the hyperparameters used to train various deep learning models, comparison of Janus kinase family of proteins, effectiveness of using both transfer and reinforcement learning, generated novel scaffolds, representative set of small molecules, and various physicochemical property distributions of the generative models (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c01060/suppl_file/ci0c01060_si_001.pdf">PDF</a>)Supporting Information 2: training and validation datasets for the case study and the dataset of generated small molecules obtained after application of all filters along with their virtual screening scores (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c01060/suppl_file/ci0c01060_si_002.xls">XLS</a>)This article has not yet been cited by other publications.

The design of compounds with desirable properties – The anti‐HIV case study

Identifying 124 new anti-HIV drug candidates in a 37 billion-compound database: an integrated approach of machine learning (QSAR), molecular docking, and molecular dynamics simulation

Artificial Intelligence-Guided De Novo Molecular Design Targeting COVID-19

Enabling rapid COVID-19 small molecule drug design through scalable deep learning of generative models

De Novo Design of Anti-COVID Drugs Using Machine Learning-Based Equivariant Diffusion Model Targeting the Spike Protein

Retro Drug Design: From Target Properties to Molecular Structures

Application of deep learning and molecular modeling to identify small drug-like compounds as potential HIV-1 entry inhibitors

Chemoinformatics and Machine Learning Approaches for Identifying Antiviral Compounds

Exploring the potential of machine learning to design antidiabetic molecules: a comprehensive study with experimental validation

Accelerating De Novo Drug Design against Novel Proteins Using Deep Learning

Computational anti-COVID-19 drug design: progress and challenges

De novo design and bioactivity prediction of SARS-CoV-2 main protease inhibitors using recurrent neural network-based transfer learning

Efficient Identification of Anti-SARS-CoV-2 Compounds Using Chemical Structure- and Biological Activity-Based Modeling

Machine learning‐guided design of potent darunavir analogs targeting HIV‐1 proteases: A computational approach for antiretroviral drug discovery

Artificial Intelligence for Autonomous Molecular Design: A Perspective

Discovery of Anti-Hiv Drugs Using Computer Aided Drug Designing Tools

Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries

The AI-driven Drug Design (AIDD) platform: an interactive multi-parameter optimization system integrating molecular evolution with physiologically based pharmacokinetic simulations

Advancing Drug Discovery with Deep Learning: Harnessing Reinforcement Learning and One-Shot Learning for Molecular Design in Low-Data Situations

Target-specific novel molecules with their recipe: Incorporating synthesizability in the design process

Integrated Molecular Modeling and Machine Learning for Drug Design